M. Pautasso

发表

Increase in platelet count in older, poor‐risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all‐trans retinoic acid

P. Pelicci, F. Lo Coco, D. Cilloni, 2005, Cancer.

ORIGINAL ARTICLE The NF-jB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance

M. Baccarani, G. Martinelli, D. Cilloni, 2006 .

CD7/CD56-positive acute myeloid leukemias are characterized by constitutive phosphorylation of the NF-kB subunit p65 at Ser536

D. Cilloni, F. Messa, F. Arruga, 2007, Leukemia.

A biparametric flow cytometry analysis for the study of reticulocyte patterns of maturation

F. Pigozzi, R. Salvo, P. Borrione, 2010, International journal of laboratory hematology.

C-reactive protein levels in the first days of life: a systematic statistical approach

M. Mussap, V. Fanos, P. Coni, 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

Unusual Clinical Presentation of Mycobacterium fortuitum Infection in an Immunocompetent Woman

A. Manzin, G. Loi, C. Serra, 2007, Journal of Clinical Microbiology.

Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

D. Cilloni, F. Messa, F. Arruga, 2010, Haematologica.

Deferasirox is a powerful NF-κ B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from intracellular iron chelation and reactive oxygen species scavenging

D. Cilloni, F. Messa, F. Arruga, 2010 .

The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance

M. Baccarani, G. Martinelli, D. Cilloni, 2006, Leukemia.

Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin

G. Scagliotti, M. Papotti, S. Novello, 2009, Molecular Cancer Therapeutics.

TCR transfer induces TCR-mediated tonic inhibition of RAG genes in human T cells.

P. Circosta, C. Giachino, L. Accomasso, 2011, Molecular immunology.

WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity.

F. Lo‐Coco, G. Martinelli, I. Iacobucci, 2010, Leukemia.

Impact of Different Concentrations of Human Recombinant Growth Hormone on T Lymphocytes

F. Pigozzi, P. Borrione, L. Di Luigi, 2012, International journal of immunopathology and pharmacology.

Physiologic modulation of natural killer cell activity as an index of Alzheimer's disease progression

F. Chiappelli, L. Saba, P. Prolo, 2007, Bioinformation.

NF‐kB inhibition as a strategy to enhance etoposide‐induced apoptosis in K562 cell line

R. Taulli, D. Cilloni, F. Messa, 2006, American journal of hematology.

The Present Status of Clinical Use of Levamisole

M. Pautasso, E. Chessa, F. Locci, 1984 .

Valproate enhances imatinib‐induced growth arrest and apoptosis in chronic myeloid leukemia cells

R. Taulli, D. Cilloni, F. Messa, 2006, Cancer.

Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.

G. Perrone, C. Panuzzo, G. Saglio, 2007, Cancer research.

Potential Targets for Immunotherapy Approaches Tumor-Specific Fusion Proteins that May Represent Positive Leukemias Result in Novel − Chromosome Alternative BCR / ABL Splice Variants in Philadelphia

G. Perrone, C. Panuzzo, G. Saglio, 2007 .

Analysis of microsatellite instability in chronic lymphoproliferative disorders

G. Gaidano, G. Saglio, C. Camaschella, 1996, Annals of Hematology.

Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer

G. Scagliotti, M. Papotti, P. Ceppi, 2012, International journal of cancer.

Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-κB in AML carrying NPM1 mutations

G. Martinelli, I. Iacobucci, D. Cilloni, 2008, Leukemia.

CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study

P. Valentino, A. Bertolotto, L. Granieri, 2014, Journal of Neuroimmunology.

Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders

G. Gaidano, G. Saglio, G. Volpe, 1995, Genes, chromosomes & cancer.

[Neo-adjuvant chemotherapy].

G. Lauria, D. Perroni, G. Grecchi, 1988, Minerva chirurgica.

Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes

A. Levis, G. Gaidano, G. Saglio, 2011, European Journal of Haematology.

Prognostic Relevance of Cytometric Quantitative Assessment in Patients with Myelodysplastic Syndromes.

A. Iavarone, A. Levis, G. Saglio, 2006 .

Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study

F. Sperli, P. Valentino, A. Bertolotto, 2023, Neurology and Therapy.

A peculiar pattern of expression of the transferrin receptor (CD71) by reticulocytes in patients given recombinant human erythropoietin (rHuEPO): a novel marker for abuse in sport?

F. Pigozzi, R. Salvo, P. Borrione, 2007, Journal of biological regulators and homeostatic agents.